PARIS — Prosecutors in Paris opened an investigation Wednesday into allegations that Chinese citizens had sought to capture sensitive French government and military data using Starlink. “Four people were brought before the investigating judge for indictment, with two of them being remanded in custody,” the public prosecutor’s office said in a statement. Investigators are looking into possible acts of “delivering information to a foreign power or a company or organization under foreign control, or to their agents, in a manner likely to harm the fundamental interests of [France],” the statement added — a crime that can lead to up to 15 years in prison. The prosecutor’s office said police had been notified last week that the arrested pair were suspected of conducting satellite interception operations from an AirBnB they had rented in the Gironde region, near the city of Bordeaux, after neighbors noticed that “a satellite dish approximately two meters in diameter” had been installed and local residents were experiencing internet outages. “The device installed was used to illegally intercept satellite downlinks, including exchanges between military entities of vital importance,” the statement added. On their visa application to enter France, the suspects said they worked for a company that focuses on “smart beams, signal recognition and satellite networks, and cooperates with universities establishing military-oriented projects.” POLITICO has reached out to the Chinese Embassy in Paris for a comment.

BRUSSELS — Disgraced British politician Peter Mandelson is facing demands to be stripped of his pension as a former European commissioner if investigators found he broke EU rules over his contact with convicted sex offender Jeffrey Epstein.  Mandelson served as a European commissioner between 2004 and 2008 and is now at the center of a spiraling scandal in Britain. Newly released files showed how Mandelson, who was a senior British minister at the time, helped provide Epstein, then a financier, with information about a €500 billion bailout to save the euro in 2010.  The European Commission is looking into whether Mandelson broke its rules, which apply even after commissioners have left office, though ethics campaigners have called for a full fraud inquiry by independent investigators. Mandelson should lose the commissioner’s pension to which he is entitled if he’s found to have breached the rules, the campaigners said.  “Given the severity of allegations concerning Peter Mandelson’s deplorable relationship with Jeffrey Epstein, the European Commission and European Anti-Fraud Office must pursue an immediate investigation to establish any potential misconduct both during and beyond his tenure as European Commissioner,” Nick Aiossa, director at Transparency International, a leading anti-corruption campaign group, told POLITICO. “Should it do so, Mandelson must be stripped of his Commissioner’s pension.” Daniel Freund, a Green MEP from Germany, condemned the lack of action and investigations against “the most powerful people on earth” over their links to the disgraced financier. “That EU commissioners were somehow involved with this universe is just outrageous,” he told POLITICO. “Taking away the pension would be justified if he broke any EU rules.” Mandelson, 72, was entitled to an inflation-linked pension reportedly worth £31,000 a year when he turned 65 for his four years as a European commissioner. This is on top of other any pensions from his time as an elected politician in the U.K. and in other roles. Mandelson did not immediately respond to a request for comment. He has previously said he was wrong to have continued his association with Epstein and apologized “unequivocally” to Epstein’s victims. In a statement, the EU’s anti-fraud office, known as OLAF, said: “We cannot provide details regarding cases which OLAF may or may not be treating. This is to protect the confidentiality of any possible investigations and of possible ensuing judicial proceedings, as well as to ensure respect for personal data and procedural rights.” In London, Britain’s Health Secretary Wes Streeting said Mandelson should lose the severance payment he was entitled to when his career as U.K. ambassador to the United States ended over the Epstein scandal. Speaking to Times Radio, Streeting also suggested Mandelson could potentially be stripped of related pension entitlements. The opposition Reform UK party said Mandelson should lose the pension he’s entitled to receive as a former government minister. Noah Keate contributed to this report.

Developed and funded by AbbVie in collaboration with the World Ovarian Cancer Coalition (the Coalition) and based on an interview with Christel Paganoni-Bruijns, chief executive officer of the Coalition, and Frances Reid, programme director of the Coalition -------------------------------------------------------------------------------- Late diagnoses, burdensome treatments and disease recurrence are realities for many women with ovarian cancer.1,2,3,4,5 Their stories are evidence of systemic challenges impacting care that policymakers have the power to combat. The World Ovarian Cancer Coalition (the Coalition), the only global ovarian cancer patient advocacy organization, is driving evidence generation to inform tangible policy reforms that could reduce the socioeconomic burden of this disease on individuals and wider societies.6 Ovarian cancer is one of the deadliest cancers affecting women in Europe, yet it remains overlooked.7,8 While other areas of women’s health benefit from policy frameworks and public awareness, ovarian cancer continues to sit in the margins, creating real human consequences. In 2022, Europe recorded the highest rates of ovarian cancer incidence and mortality worldwide.8 Only 40 percent of women in Europe remain alive five years after being diagnosed with ovarian cancer, with advanced-stage diagnoses often having poorer outcomes.8 Despite this, ovarian cancer remains absent from many national cancer plans and there is still no unified European policy framework to address it.  In partnership with European patient groups, the Coalition is convening a series of workshops for ovarian cancer survivors to share their experiences. Alongside leading clinicians and advocates, the Coalition is leveraging these testimonies to develop policy recommendations to inform national and European cancer strategies. Christel Paganoni-Bruijns, the Coalition’s chief executive officer, and Frances Reid, programme director and Every Woman Study lead, share their insights into the challenges women with ovarian cancer face and how policy changes can offer improved support. The hidden emotional and physical cost  There are education and awareness gaps that can impede diagnosis and prioritization. Many women believe that cervical cancer screening (otherwise known as the Pap smear) can detect ovarian cancer.9 Another widespread misconception is that ovarian cancer has no symptoms until very advanced stages.10 However, the Coalition’s Every Woman Study (2021) found that nine in 10 women do experience symptoms, even during the early stages.11  “These misconceptions cause real harm. They delay diagnosis, they delay action and they stop women from being heard,” Reid comments.  The ovarian cancer journey can be distressingly complex. Women frequently undergo major surgery, multiple rounds of treatment and long recovery periods.4,12,13 Even after treatment ends, the fear of recurrence can cast a shadow over daily life.  Ovarian cancer often strikes when many women are still working, caring for children, supporting aging parents and contributing to their communities in a variety of ways. 14,15 When they fall ill, the consequences ripple outwards. Some partners have to reduce their working hours or leave employment entirely to care for their loved ones.16 Families may take on emotional strain and financial pressure that can carry lasting impacts.17,18  Reid says: “These women are mothers, daughters, employees, carers, community anchors. When they are affected, the impact is not only personal — it is economic, social and predictable.” The Coalition’s socioeconomic burden study explored the cost to health services, the impact of informal caregiving, productive time lost by patients traveling to and receiving care, and longer-term productivity impacts.17 It found that the majority of the socioeconomic impact of ovarian cancer does not come from health service costs, but from the value of lives lost.17 Across the 11 countries examined, ill-health from ovarian cancer led to lost labor productivity equivalent to 2.5 million days of work.17 In the U.K. alone, productivity losses amounted to over US$52 million per year.17 In 2026, the Coalition will look further into the socioeconomic impact across high-income countries across Europe. Despite this measurable burden, ovarian cancer remains under-prioritized in health planning and funding decisions. Why women still struggle to get the care they need  Across Europe, many women face delays at various stages along their journey, some due to policy and system design choices. For example, without screening methods for early detection, diagnosis relies heavily on recognizing symptoms and receiving timely referrals.1,19,20 Yet many women often struggle to access specialists or face long waits for investigations.2,11,21   While Europe benefits from world-class innovation in ovarian cancer research, access to that innovation can be inconsistent. Recently published data from the European Federation of Pharmaceutical Industries and Associations (EFPIA) found that average time to availability for oncology products in Europe continues to increase, with 2024 data showing time from approval to access was 33 days slower than in 2023 and 66 days slower than in 2022.22 In 2024, it took an average of 586 days — or ~19 months — for patients to access new therapies after approval, with significant variation between countries.22 Delays in treatment impact prognosis and survival for patients with ovarian cancer.23 The challenges in care also extend to psychological and emotional support. The Every Woman Study found that only 28 percent of women were offered mental health support, despite the known vulnerabilities throughout treatment, recovery and recurrence.12   Paganoni-Bruijns and Reid reinforce that through the Coalition’s work, they have often found that “women feel unseen and unheard. They see progress in other cancers and ask: why not us?” What a better future looks like A better future starts with addressing ovarian cancer as part of a holistic vision and plan for women’s health. Europe has the foundational frameworks, infrastructure and clinical expertise to lead the way. What is needed now is political attention and policy alignment that includes ovarian cancer as part of these broader programs.  Paganoni-Bruijns comments: “We cannot keep treating gynecological cancers as if they exist in separate boxes. Women experience their health as one reality, so policies must reflect that.”  Existing structures in breast and cervical cancer offer valuable lessons. Across Europe, millions of women already move through screening programs, health promotion initiatives and established diagnostic pathways.24 These systems could be used to increase awareness of ovarian cancer symptoms, improve referral routes and access to specialist care, and support earlier detection. Increased investment in genetic and biomarker testing, as well as emerging early detection research, can be accelerated by aligning with these established programs. The Coalition is partnering with global experts to translate these lessons into the first-ever evidence-based framework for ovarian cancer mortality rate reduction, however, policy action at the regional and national level must keep pace.  The EU-funded DISARM project is a promising example of the progress underway to help Europe ‘disarm’ the threat of ovarian cancer. DISARM is a coordinated, multi-country effort to strengthen ovarian cancer risk assessment, validate affordable early-detection tools and understand how these innovations can be implemented within real-world health systems. Crucially, it is designed both to generate evidence and to address feasibility, uptake and system readiness, the factors that, together, determine whether innovation actually reaches patients.   As Paganoni-Bruijns explains, “DISARM shows what progress looks like when science, policy and patient experience are designed to work together. It is not about a single breakthrough or ‘quick fix’, but about building the conditions for earlier detection — through better risk assessment, validated tools and systems that are ready to use them.”  Yet projects like DISARM, while essential, cannot carry the burden alone. Without a cohesive European or global World Health Organization framework for ovarian cancer, progress remains fragmented, uneven and vulnerable to delay. Europe has often set the pace for global cancer policy and ovarian cancer should be no exception. By recognizing ovarian cancer as a priority within European women’s health, policymakers can be part of setting the global standard for a new era of coordinated and patient-centered care. Paganoni-Bruijns shares the Coalition’s call-to-action: “The systems exist. The evidence exists. We know that we need to include ovarian cancer in national cancer plans, improve diagnostic pathways, strengthen genetic testing and commit to EU-level monitoring. What is missing is prioritization. With leadership and accountability, ovarian cancer does not have to remain one of Europe’s deadliest cancers.” The stakes are rising and the window for meaningful action is narrowing. But with focused leadership, Europe can change the trajectory of ovarian cancer. Women across the continent deserve earlier diagnoses, access to innovation and the chance to live not just longer, but better. To understand why action on ovarian cancer cannot wait, listen to the Coalition’s Changing the Ovarian Cancer Story podcast series, or visit the Coalition’s website. -------------------------------------------------------------------------------- References 1 Rampes S, et al. Early diagnosis of symptomatic ovarian cancer in primary care in the UK: opportunities and challenges. Prim Health Care Res Dev. 2022;23:e52. 2 Funston G, et al. Detecting ovarian cancer in primary care: can we do better? Br J Gen Pract. 2022;72:312-313.  3 Tookman L, et al. Diagnosis, treatment and burden in advanced ovarian cancer: a UK real-world survey of healthcare professionals and patients. Future Oncol. 2024;20:1657-1673.  4 National Cancer Institute. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq [Last accessed: January 2026]. 5 Beesley et al. Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns). Gynecologic Oncology 164 (2022):437-445.  6 World Ovarian Cancer Coalition. About the World Ovarian Cancer Coalition. Available at: https://worldovariancancercoalition.org/about-us/ [Last accessed: January 2026]. 7 Manzano A, Košir U, Hofmarcher T. Bridging the gap in women’s cancers care: a global policy report on disparities, innovations and solutions. IHE Report 2025:12. The Swedish Institute for Health Economics (IHE); 2025. 8 ENGAGe. Ovarian Cancer. Available at: https://engage.esgo.org/gynaecological-cancers/ovarian-cancer/ [Last accessed: January 2026].  9 Target Ovarian Cancer. Driving change through knowledge – updated NHS cervical screening guide. Available at: https://targetovariancancer.org.uk/news/driving-change-through-knowledge-updated-nhs-cervical-screening-guide [Last accessed: January 2026]. 10 Goff BA, et al. Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics. JAMA. 2004;291(22):2705–2712.  11 Reid F, et al. The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. Int J Gynecol Cancer. 2021;31:238-244.  12 National Health Service (NHS). Ovarian cancer. Treatment. Available at: https://www.nhs.uk/conditions/ovarian-cancer/treatment/ [Last accessed: January 2026].  13 Cancer Research UK. Recovering from ovarian cancer surgery. Available at: https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/treatment/surgery/recovering-from-surgery [Last accessed: January 2026]. 14 National Health Service (NHS). Ovarian cancer. Causes. Available at: https://www.nhs.uk/conditions/ovarian-cancer/causes/ [Last accessed: January 2026].  15 American Cancer Society. Ovarian Cancer Risk Factors. Available at: https://www.cancer.org/cancer/types/ovarian-cancer/causes-risks-prevention/risk-factors.html [Last accessed: January 2026].  16 Shukla S, et al. VOCAL (Views of Ovarian Cancer Patients and Their Caregivers – How Maintenance Therapy Affects Their Lives) Study: Cancer-Related Burden and Quality of Life of Caregivers [Poster]. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe; 2022 Nov 6–9; Vienna, Austria. 17 Hutchinson B, et al. Socioeconomic Burden of Ovarian Cancer in 11 Countries. JCO Glob Oncol. 2025;11:e2400313. 18 Petricone-Westwood D, et al.An Investigation of the Effect of Attachment on Distress among Partners of Patients with Ovarian Cancer and Their Relationship with the Cancer Care Providers. Current Oncology. 2021;28(4):2950–2960.  19 World Ovarian Cancer Coalition. Ovarian Cancer Testing & Detection. Available at: http://worldovariancancercoalition.org/about-ovarian-cancer/detection-testing/ [Last accessed: January 2026]. 20 National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Available at: https://www.nice.org.uk/guidance/ng12/resources/suspected-cancer-recognition-and-referral-pdf-1837268071621 [Last accessed: January 2026]. 21 Menon U, et al. Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP). Br J Cancer. 2022;127:844-854.  22 European Federation of Pharmaceutical Industries and Associations (EFPIA). New data shows no shift in access to medicines for millions of Europeans. Available at: https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/new-data-shows-no-shift-in-access-to-medicines-for-millions-of-europeans/ [Last accessed: January 2026].  23 Zhao J, et al. Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database. J Cancer. 2024;15:473-483.  24 European Commission. Europe’s Beating Cancer Plan: Communication from the commission to the European Parliament and the Council. Available at: https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf [Last accessed: January 2026].  -------------------------------------------------------------------------------- ALL-ONCOC-250039 v1.0  February 2026 -------------------------------------------------------------------------------- Disclaimer POLITICAL ADVERTISEMENT * The sponsor is AbbVie * The ultimate controlling entity is AbbVie More information here.

The UK has historically been a global leader in life sciences innovation, but recent statistics paint a worrying picture for medicines access. The right policy can start to reverse this. We are living in a time where the intersection between breakthrough science, technology and data insights has the potential to transform treatment options for some of the toughest health conditions faced by patients in the UK. The UK has long played a central role in driving innovation when it comes to healthcare, and at Johnson & Johnson (J&J) we were pleased to see some positive signs from the Government at the end of 2025, illustrating an intent to reverse a decade of decline of investment in how the UK values innovative treatments. It was a positive first step, but now the real work begins to enable us to deliver the best possible outcomes for UK patients. To achieve this, our focus must be on ensuring our health system is set up to match the pace and gain the benefits of innovation that science provides. We need a supportive medicines environment that fully fosters growth, because even the most pioneering drugs and therapies are only valuable if they can be accessed by patients when they need them most. > even the most pioneering drugs and therapies are only valuable if they can be > accessed by patients when they need them most. At J&J, we are proud to have been part of the UK’s health innovation story for more than a century. We believe that turning ambition into delivery requires a clearer focus on the foundations that enable innovation to reach patients. We have had a substantial and long-term economic presence, with our expertise serving as the grounds for successful partnerships with patients, healthcare providers, clinical researchers and the NHS. Recent national developments are a step in the right direction The UK Government’s recent announcements on the life sciences industry are an important move to help address concerns around medicines access, innovation and the UK’s international standing. This includes a welcome planned increase to the baseline cost-effectiveness threshold (the first change to be made since its introduction in the early 2000s). While it is crucial to get this implemented properly, this seems like a step in the right direction — providing a starting point towards meaningful policy reform, industry partnership and progress for patients. The true impact of stifling medicine innovation in the UK compared with our peers These positive developments come at a critical time, but they do not fix everything. Over the past decade, spending on branded medicines has fallen in real terms, even as the NHS budget has grown by a third.[i] Years of cost-containment have left the UK health system ill-prepared for the health challenges of today, with short-term savings creating long-term consequences. Right now, access to innovative medicines in the UK lags behind almost every major European country[ii]; the UK ranks 16th and 18th among 19 comparable countries for preventable and treatable causes of mortality.[iii]These are conditions for which effective medicines already exist. Even when new medicines are approved, access is often restricted. One year after launch, usage of innovative treatments in England is just over half the average of comparator countries such as France, Germany and Spain.[iv] The effect is that people living with cancer, autoimmune conditions and rare diseases wait longer to access therapies that are already transforming lives elsewhere in Europe. And even at its new level, the UK’s Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) clawback rate remains higher than in comparable countries.[v] J&J is committed to working together to develop a new pricing and access framework that is stable, predictable and internationally competitive — enabling the UK to regain its position as a leading destination for life sciences. Seeing the value of health and medicines investment as a catalyst for prosperity and growth Timely access to the right treatment achieves two things; it keeps people healthy and prevents disease worsening so they can participate in society and a thriving economy. New research from the WifOR Institute, funded by J&J, shows that countries that allocate more resources to health — especially when combined with a skilled workforce and strong infrastructure — consistently achieve better outcomes.[vi] > Timely access to the right treatment achieves two things; it keeps people > healthy and prevents disease worsening so they can participate in society and > a thriving economy. The UK Government’s recent recognition of the need for long-term change, setting out plans to increase investment in new medicines from 0.3 percent of GDP to 0.6 percent over the next 10 years is positive. It signals a move towards seeing health as one of our smartest long-term investments, underpinning the UK’s international competitiveness by beginning to bring us nearer to the levels in other major European countries. This mindset shift is critical to getting medicines to patients, and the life sciences ecosystem, including the pharmaceutical sector as a cornerstone, plays a pivotal role. It operates as a virtuous cycle — driven by the generation, production, investment in, access to and uptake of innovation. Exciting scientific developments and evolving treatment pathways mean that we have an opportunity to review the structures around medicines reimbursement to ensure they remain sustainable, competitive and responsive. At J&J, we have the knowledge and heritage to work hand-in-hand with the Government and all partners to achieve this. Together, we can realise the potential of medicine innovation in the UK Patients have the right to expect that science and innovation will reach them when they need it. Innovative treatments can be transformative for patients, meaning an improved quality of life or more precious time with loved ones. We fully support the Government’s ambitions for life sciences and the health of the nation. Now is the moment to deliver meaningful change — the NHS, Government and all system partners, including J&J, must look at what valuing innovation actually means when it comes to modernising the frameworks and mechanisms that support access and uptake. Practical ways to do this include: * Establishing a new pricing and access framework that is stable, predictable and internationally competitive. * Evolving medicines appraisal methods and processes, to deliver on the commitments of the UK-US Economic Prosperity Deal. * Adapting thresholds and value frameworks to ensure they are fit for the future — in the context of wider system pressures, including inflation, and the evolution of medical innovation requiring new approaches to assessment and access. > the NHS, Government and all system partners, including J&J, must look at what > valuing innovation actually means when it comes to modernising the frameworks > and mechanisms that support access and uptake. By truly recognising the value of health as an investment, rather than as a cost, we can return the UK to a more competitive position. The direction of travel is positive. At J&J, we stand ready to work in partnership to help ensure the UK is once again the best place in the world to research, develop and access medicines. Follow Johnson & Johnson Innovative Medicine UK on LinkedIn for updates on our business, our people and our community. CP-562703 | January 2026 -------------------------------------------------------------------------------- [i] House of Commons Library (2026). ‘NHS Funding and Expenditure’ Research Briefing. Available at: https://commonslibrary.parliament.uk/research-briefings/sn00724/ (Accessed January 2026). [ii] IQVIA & EFPIA (2025). EFPIA Patients W.A.I.T Indicator 2024 Survey. Available at: https://efpia.eu/media/oeganukm/efpia-patients-wait-indicator-2024-final-110425.pdf. (Accessed January 2026) [iii] The Kings Fund (2022). ‘How does the NHS compare to the health care systems of other countries?’ Available at: https://www.kingsfund.org.uk/insight-and-analysis/reports/nhs-compare-health-care-systems-other-countries (Accessed January 2026) [iv] Office for Life Sciences (2024). Life sciences competitiveness indicators 2024: summary. Available at: https://www.gov.uk/government/publications/life-sciences-sector-data-2024/life-sciences-competitiveness-indicators-2024-summary (Accessed January 2026). [v] ABPI. VPAG payment rate for newer medicines will be 14.5% in 2026. December 2025. Available at: https://www.abpi.org.uk/media/news/2025/december/vpag-payment-rate-for-newer-medicines-will-be-145-in-2026/. (Accessed January 2026). [vi] WifOR Institute (2025). Healthy Returns: A Catalyst for Economic Growth and Resilience. Available at: https://www.wifor.com/en/download/healthy-returns-a-catalyst-for-economic-growth-and-resilience/?wpdmdl=360794&refresh=6942abe7a7f511765977063. (Accessed January 2026).

BRUSSELS — The European Union is pressing ahead with talks to grant United States border authorities unprecedented access to Europeans’ data, despite growing concerns about American surveillance. The European Commission is brokering a deal to exchange information about travelers, including fingerprints and law enforcement records, so the U.S. can determine if they “pose a risk to public security or public order,” according to official documents. Commission officials flew to Washington last week for the first round of negotiations, according to two people familiar with the matter. The Trump administration’s request for deeper access comes after the U.S. border agency in December proposed reviewing five years of social media history. Talks are happening as the U.S. Immigration and Customs Enforcement (ICE) service is under heavy scrutiny for its use of surveillance technology against protesters in cities such as Minneapolis. The negotiations should be “put on hold” until the security and privacy of citizens in the EU and U.S. can be guaranteed, liberal European Parliament member Raquel García Hermida-van der Walle said in an interview. Romain Lanneau, a legal researcher with surveillance watchdog Statewatch, said police databases in Europe could contain information on anyone from protesters to journalists who might be considered a “threat,” and that — under the deal being discussed — this information would be at the fingertips of U.S. border authorities who could refuse those people entry to the United States or even detain them. European regulators are “very cautiously looking at what’s happening in the United States,” Wojciech Wiewiórowski, the EU’s in-house data protection supervisor, told POLITICO. Europe “has to be careful” about how it allows the data of Europeans to flow to the U.S., he said.  Hermida-van der Walle in January co-signed a letter by six prominent lawmakers calling on the Commission to stand down given the “current geopolitical context,” despite Washington’s admonition that failure to reach a deal will mean Europeans lose access to its visa waiver program. UNPRECEDENTED ACCESS The U.S. is seeking access to information including biometric data such as fingerprints that is stored on national databases in European countries, according to an explanatory note sent to national experts. The data would be used to “address irregular migration and to prevent, detect, and combat serious crime and terrorist offences,” the note said. In an earlier opinion on the deal, the European Data Protection Supervisor (EDPS) — a watchdog that advises the Commission on privacy policies — noted the deal would be the first of its kind to enable “large-scale sharing of personal data … for the purpose of border and immigration control” with a non-EU country. The Commission would negotiate a framework deal that would serve as a template for bilateral agreements called Enhanced Border Security Partnerships (EBSPs), which national governments agree with Washington. EU countries in December signed off on the Commission’s request to start talks with the U.S. Washington is pressuring its EU counterparts by imposing a deadline for the bilateral deals to be agreed by the end of 2026. If countries fail to reach a deal with the U.S. they risk being cut from the latter’s visa waiver program. The U.S has made it mandatory for all countries that are part of the visa waiver program to have an EBSP in place. “The pressure which the United States is extorting on our member states, the threats that if you don’t agree with this we will cancel your access to the visa waiver program, that is an element of blackmail that we cannot let go,” Hermida-van der Walle said. The EDPS watchdog has cautioned that the scope of data sharing should be as narrow as possible, with clear justifications for every query; transparency around how the data is used; and judicial redress available in the U.S. for any person. Commission spokesperson Markus Lammert emphasised at a recent press briefing that the framework being negotiated will involve “clear and robust safeguards on data protection,” and will ensure “a non-systematic nature of the information exchange and that the exchange is limited to what is strictly necessary to achieve the objectives of this cooperation.”  US PRIVACY UNDER PRESSURE Access to the data is the latest issue putting pressure on a troubled relationship between the U.S. and the EU on data privacy. Since whistleblower Edward Snowden in 2013 revealed U.S. mass surveillance practices affecting Europeans, the EU has tightened controls on how Washington handles Europeans’ data. Since the return of Donald Trump as president last year, officials and rights groups have deplored a move by the U.S. administration to gut a key privacy watchdog tasked with overseeing privacy safeguards in place to protect Europeans. The Trump administration has also been ramping up mass surveillance of citizens by federal agencies like ICE, including through contracts with Israeli spyware company Paragon, surveillance giant Palantir and other firms. Capgemini, a prominent French IT firm, on Sunday said it was selling off its American activities after it faced political backlash from the French government that its software was being used by ICE authorities. Civil rights groups, lawmakers and other watchdogs fear the new EU-U.S. data sharing deals would add to backsliding on privacy rights.    “The current initiatives are being presented as toward counter-terrorism, but a lot of them are actually adopted for the chilling effect [on political activism],” Statewatch’s Lanneau said. Hermida-van der Walle, the liberal lawmaker, warned: “If people have to go to the United States, if it’s not a choice but something that they have do, there is a risk of self-censoring.”  “This comes from an administration who claims to be the biggest defender of free speech. What they’re doing with their actions is curtailing the possibility of people to express themselves freely, because otherwise they might not get access into the country,” she said.

A group of researchers is suing Elon Musk’s X to gain access to data on Hungary’s upcoming elections to assess the risk of interference, they told POLITICO. Hungary is set to hold a highly contentious election in April as populist nationalist Prime Minister Viktor Orbán faces the toughest challenge yet to his 16-year grip on power. The lawsuit by Democracy Reporting International (DRI) comes after the civil society group, in November, applied for access to X data to study risks to the Hungarian election, including from disinformation. After X rejected their request, the researchers took the case to the Berlin Regional Court, which said it is not competent to rule on the case. DRI — with the support of the Society for Civil Rights and law firm Hausfeld — is now appealing to a higher Berlin court, which has set a hearing date of Feb. 17. Sites including X are obliged to grant researchers access to data under the European Union’s regulatory framework for social media platforms, the Digital Services Act, to allow external scrutiny of how platforms handle major online risks, including election interference. The European Commission fined X €40 million for failing to provide data access in December, as part of a €120 million levy for non-compliance with transparency obligations. The lawsuit is the latest legal challenge to X after the researchers went down a similar path last year to demand access to data related to the German elections in February 2025. A three-month legal drama, which saw a judge on the case dismissed after X successfully claimed they had a conflict of interest, ended with the court throwing out the case. The platform said that was a “comprehensive victory” because “X’s unwavering commitment to protecting user data and defending its fundamental right to due process has prevailed.” The researchers also claimed a win: The court threw the case out on the basis of a lack of urgency, as the elections were well in the past, said DRI. The groups say the ruling sets a legal precedent for civil society groups to take platforms to court where the researchers are located, rather than in the platforms’ legal jurisdictions (which, in X’s case, would be Ireland). X did not respond to POLITICO’s request for comment on Monday.

The Senate passed a compromise spending package Friday, clearing a path for Congress to avert a lengthy government shutdown. The 71-29 vote came a day after Senate Democrats and President Donald Trump struck a deal to attach two weeks of Homeland Security funding to five spending bills that will fund the Pentagon, State Department and many other agencies until Sept. 30. Only five of 53 Republicans voted against it after Trump publicly urged lawmakers Thursday to approve the legislation. Democrats were split, with 24 of 47 caucus members opposing the package. The Senate’s vote won’t avert a partial shutdown that will start early Saturday morning since House lawmakers are out of town and not scheduled to return until Monday. During a private call with House Republicans Friday, Speaker Mike Johnson said the likeliest route to House passage would be bringing the package up under a fast-track process Monday evening. That would require a two-thirds majority — and a significant number of Democratic votes. The $1.2 trillion package could face challenges in the House, especially from conservative hard-liners who have said they would vote against any Senate changes to what the House already passed. Many House Democrats are also wary of stopgap funding for DHS, which would keep ICE and Border Patrol funded at current levels without immediate new restrictions. Senate Majority Leader John Thune said he had been in constant contact with Johnson “for better or worse” about getting the funding deal through the House, predicting that the Louisiana Republican is “prepared to do everything he can as quickly as possible.” “Hopefully things go well over there,” he added. If the Trump-blessed deal ultimately gets signed into law, Congress will have approved more than 95 percent of federal funding — leaving only a full-year DHS bill on its to-do list. Congress has already funded several agencies, including the departments of Agriculture, Veterans Affairs and Justice. “These are fiscally responsible bills that reflect months of hard work and deliberation from members on both parties and both sides of the Capitol,” Senate Appropriations Committee Chair Susan Collins (R-Maine) said before the final vote. The Office of Management and Budget has issued shutdown guidance for agencies not already funded, which include furloughs of some personnel. Republicans agreeing to strip out the full-year DHS bill and replace it with a two-week patch is a major win for Democrats. They quickly unified behind a demand to split off and renegotiate immigration enforcement funding after federal agents deployed to Minnesota fatally shot 37-year-old U.S. citizen Alex Pretti last week. Senate Minority Leader Chuck Schumer, who helped negotiate the final deal, took a victory lap after the vote, saying “the agreement we reached today did exactly what Democrats wanted.” But Democrats will still need to negotiate with the White House and congressional Republicans about what, if any, policy changes they are willing to codify into law as part of a long-term bill. Republicans are open to some changes, including requiring independent investigations. But they’ve already dismissed some of Democrats’ main demands, including requiring judicial warrants for immigration arrests. “I want my Republican colleagues to listen closely: Senate Democrats will not support a DHS bill unless it reins in ICE and ends the violence,” Schumer said. “We will know soon enough if your colleagues understand the stakes.” Republicans have demands of their own, and many believe the most likely outcome is that another DHS patch will be needed. Sen. Lindsey Graham (R-S.C.), for instance, wants a future vote on legislation barring federal funding for cities that don’t comply with federal immigration laws. Other Republicans and the White House have pointed to it as a key issue in the upcoming negotiations. “I am demanding that my solution to fixing sanctuary cities at least have a vote. You’re going to put ideas on the floor to make ICE better? I want to put an idea on the floor to get to the root cause of the problem,” Graham said. The Senate vote caps off a days-long sprint to avoid a second lengthy shutdown in the span of four months. Senate Democrats and Trump said Thursday they had a deal, only for it to run into a snag when Graham delayed a quick vote as he fumed over a provision in the bill, first reported by POLITICO, related to former special counsel Jack Smith’s now-defunct investigation targeting Trump. Senate leaders ultimately got the agreement back on track Friday afternoon by offering votes on seven changes to the bill, all of which failed. The Senate defeated proposals to cut refugee assistance, strip out all earmarks from the package and redirect funding for ICE to Medicaid, among others. Graham raged against the House’s move to overturn a law passed last year allowing senators to sue for up to $500,000 per incident if their data had been used in former special counsel Jack Smith’s investigation into the 2020 election. But he backed off his threats to hold up the bill after announcing that leaders had agreed to support a future vote on the matter. “You jammed me,” Graham said on the floor Friday. “Speaker Johnson, I won’t forget this.” Meredith Lee Hill and Jennifer Scholtes contributed to this report.

German industrial giant Bosch on Friday confirmed plans to cut 20,000 jobs after profits nearly halved last year, underlining the mounting strain on Germany’s once-dominant manufacturing sector and increasing the pressure on politicians in Berlin to find a solution. Official data released Friday also showed Germany’s unemployment rate, unadjusted for seasonal factors, rising to 6.6 percent — the highest level in twelve years. The number of unemployed people surpassed three million in January. “Economic reality is also reflected in our results,” Bosch CEO Stefan Hartung said, describing 2025 as “a difficult and, in some cases, painful year” for the company, which is a leading supplier of parts for cars. The move lands amid a deepening slump in the country’s automotive industry, long the backbone of German manufacturing. The sector has been shedding jobs rapidly: A 2025 study by EY found that more than 50,000 automotive positions were cut in Germany last year alone. Germany’s automotive downturn has become a wider political test for the government in Berlin and Europe more widely. Once the economy’s crown jewel, the industry is now being challenged by current policy on electric vehicles, energy costs and aggressive competition from Chinese manufacturers. As suppliers weaken, the risk is shifting from lower profits to a lasting loss of competitiveness. With layoffs rising and investment decisions being delayed, Chancellor Friedrich Merz’s government is coming under growing pressure from workers, unions and industry leaders to rethink Germany’s industrial strategy — as doubts spread domestically and across Europe about the country’s ability to remain an economic powerhouse.

The three parties that have formed the new Dutch minority government have pitched raising the European minimum age for social media to 15, according to coalition plans unveiled on Friday. With the move, the Netherlands is the latest country to push for a de facto social media ban at 15, following France’s example. The three Dutch parties — the centrist D66, the Christian Democrat CDA and the liberal VVD — will still need to seek support for their proposals, as they hold only 66 of 150 seats in the Dutch parliament. The parties want an “enforceable European minimum age of 15 for social media, with privacy-friendly age verification for young people, as long as social media are not sufficiently safe,” they write in the plans. The current EU minimum age stands at 13. The coalition program also envisions a crackdown on screen time through prevention and health guidance, and stricter smartphone rules in schools, which will require devices to remain at home or in a locker. In June of last year, the previous Dutch government issued guidance to parents to wait until age 15 before allowing their children to use social media. Earlier this week, a bill to ban social media for users under 15 passed the French parliament’s lower chamber and could take effect in September. Australia paved the way by banning children from a range of platforms in December. The new Dutch government also is launching a push to become more digitally sovereign and to reduce “strategic dependencies” in areas such as cloud services and data. Eliza Gkritsi contributed to this report.

BRUSSELS — An identity tool that underpins the digital lives of Dutch people and has partly fallen into American hands is prompting the country to reconsider its reliance on U.S. technology. In the Netherlands, almost every citizen regularly uses the online identification tool DigiD to book a doctor’s appointment, buy a house or access online public services. With a Dutch supplier of the tool in the process of being acquired by a U.S. technology company, that’s prompting concerns that the Netherlands is giving away critical technology at a moment of heightened sensitivity around the country’s wholesale use of American services. As Dutch lawmakers in the parliament’s digital affairs committee met Tuesday to debate the issue, they received a petition signed by 140,000 people calling on the government to block the acquisition. “If the Dutch government does something that [U.S. President Donald] Trump doesn’t like, he can shut down our government with one push of a button,” the petition reads. “That’s a big danger.”  The debate over DigiD has put the spotlight on a topic that has been simmering for a while.  With the Netherlands a long-time proponent of the transatlantic relationship, Dutch society is built on U.S. technology and IT services — as is the country’s government. That’s now seen as a glaring security issue as Trump fires off threats toward Europe.  Two-thirds of the domain names of Dutch governments, schools and other critical companies rely on at least one U.S. cloud provider, research by the Dutch public broadcaster showed Sunday, with Microsoft the frontrunner.  “We are the most Microsoft-loving country of the whole world,” said Bert Hubert, a Dutch cybersecurity expert and former intelligence watchdog. “The Dutch government uses more Microsoft than the U.S. government.” OMNIPRESENT Questions over DigiD’s relationship with U.S. technology started in early November.  U.S. cloud provider Kyndryl, a recent spin-off of the well-known U.S. tech company IBM, announced at the time that it would acquire Dutch cloud provider Solvinity. That company doesn’t own the online identification tool DigiD but provides the platform on which it runs.  To Dutch people, DigiD is ubiquitous in their lives. “Every time you want to rent a house in the Netherlands, make an appointment with the doctor or do something in the hospital, you have to go through DigiD,” Hubert said.  Potential U.S. control over such an omnipresent tool triggered fierce pushback.  Last year the International Criminal Court, based in The Hague, ditched Microsoft as a service provider amid concerns about U.S. sanctions targeting the court. | Erik S. Lesser/EPA Putting vital digital infrastructure in American hands “raises Dutch vulnerability for outages, manipulation or even blackmail,” a group of experts, among them Hubert, said in a letter their lawyers sent mid-January to the ministry service in charge of scrutinising acquisitions.   The acquisition could also endanger the security of Dutch people’s sensitive personal data, lawmakers and experts argue. “The risk is that it falls under the U.S. Cloud Act, which says that it doesn’t matter if data is hosted on EU soil, but if the service is done by a U.S. company, then the [U.S.] government can ask for that data,” said Barbara Kathmann, lawmaker of the GreenLeft-Labour party and expert in digital affairs.  The Dutch Economy Ministry is now looking into the deal and whether it raises national security concerns, a ministry representative said in the Dutch parliament last week. Kyndryl said in a statement that it “always lived up to relevant Dutch and European requirements for the security of customers’ data and will continue to comply with existing obligations of Solvinity to its customers.” CAUTIONARY TALE The Solvinity acquisition has put the spotlight on a topic that has been simmering for a while.  Last year the International Criminal Court, based in The Hague, ditched Microsoft as a service provider amid concerns about U.S. sanctions targeting the court.  The ICC case and the Solvinity acquisition should serve as a cautionary tale for Europe to start mapping its reliance on the U.S. and nurturing European alternatives, said Sarah El Boujdaini, a lawmaker for the centrist D66 — the party of the incoming prime minister Rob Jetten. “We need to have a wider look at where our most vulnerable dependencies are, where we need to take back control, and where we need to procure more from European companies,” said El Boujdaini.  That should include a particular focus on government services and services that people access continually, several interviewees said. “Traditional government services should not be outsourced to other countries, especially not countries that are willing and have shown to be capable of weaponizing those dependencies,” said Dutch liberal European Parliament lawmaker Bart Groothuis.  “Of course [the government] should make use of the services of ICT providers,” said Hubert, “but what you should not do is give a part of your society that you depend on 24 hours a day to a company that can be acquired.”